126 articles - From Friday Apr 03 2026 to Friday Apr 10 2026
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Clin Gastroenterol Hepatol |
|---|
| AGA Clinical Practice Update on the Use of Elecrosurgery in Therapeutic Endoscopy: Expert Review.
BEST PRACTICE ADVICE 12: Endoscopists should understand how to optimally deliver electrosurgical energy to achieve the desired sphincterotomy at the time of endoscopic retrograde cholangiopancreatography while minimizing the risk of immediate/delayed bleeding and pancreatitis. BEST PRACTICE ADVICE 13: Endoscopists performing third-space endoscopy should have in-depth understanding of how to optimize the desired tissue effects while minimizing any off-target tissue damage. |
| Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease.
This updated international consensus provides practical algorithms that integrate noninvasive testing with recently approved pharmacologic therapies for MASLD, addressing current variability in clinical practice and supporting standardized implementation of risk-based care. |
meta-analyses and systematic reviews
| Gastroenterology |
|---|
| Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis.
Patient navigation and mailed FIT outreach are the most effective strategies for increasing colorectal cancer screening uptake, particularly in low baseline uptake populations. Educational multimedia shows promise in recent years and high baseline uptake settings, offering a scalable alternative. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
| Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia-Results of a Post Hoc Analysis of the Phase 3 PALISADE Study.
Plozasiran significantly lowered circulating TG levels, with substantial reduction in recurrent AP for participants with very severe hypertriglyceridemia and history of AP. Plozasiran is the first therapy to demonstrate a statistically significant reduction in recurrent AP in a prospective randomised trial of patients with familial chylomicronaemia syndrome (FCS). |
| Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation.
Liver biopsy provides limited additional diagnostic value in ANA-positive, non-cirrhotic patients with alanine aminotransferase < 101 U/L and no alternative suspected aetiology. In such cases, the procedure can be safely deferred, reserving biopsy for higher enzyme elevations or unclear differential diagnoses. |
| Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss.
HBcrAg dynamics more accurately predict CF, while HBsAg dynamics better predict HBsAg loss after NA cessation, supporting their complementary roles in clinical practice and suggesting distinct biological mechanisms underlying their production. |
| HBsAg Quantification-Based Models for Predicting Hepatocellular Carcinoma Risk in Nucleos(t)ide Analogs-Experienced Patients With Chronic Hepatitis B: The HBsAg-HCC Score.
By incorporating HBsAg quantification, a virus-specific marker often missing from conventional models, the HBsAg-HCC Score offers a more comprehensive and accurate approach to HCC risk stratification in NAs-experienced CHB patients, addressing a critical limitation of existing models directly. |
| Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.
In addition to an established anticholestatic effect, seladelpar improved pruritus severity and distribution, itch-related sleep disturbance and measures of fatigue in patients with PBC and pruritus, indicating clinically relevant improvements in itch and other quality of life benefits. |
| Am J Gastroenterol |
| An Enhanced Treatment Algorithm Targeting Mucosal Healing is Effective and Safe in Older Patients with Crohn's Disease: A Post-hoc Analysis of the REACT2 Trial.
EC was effective and not associated with increased risk compared with SC in older patients with Crohn's disease. |
| Association of Body Mass Index with Disorders of Gut-Brain Interaction: A Large Global Population-Based Analysis.
Higher, but not lower, BMI is independently associated with increased prevalence and symptom burden of DGBI. Obesity confers the highest odds for overlapping disorders and psychological disturbances, underscoring the importance of integrated metabolic and behavioral management strategies. |
| Clin Gastroenterol Hepatol |
| A MACHINE-BASED LEARNING MODEL FOR RECURRENCE PREDICTION AND TIMING AFTER ENDOSCOPIC ERADICATION THERAPY FOR BARRETT'S ESOPHAGUS.
This US-based externally validated tool accurately predicts BE and BE-related neoplasia recurrence and timing post EET. This practical tool may help provide a personalized approach to surveillance strategies. |
| American Gastroenterological Association-North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Pediatric Functional Constipation Clinical Care Pathway.
The AGA-NASPGHAN Pediatric Functional Constipation Clinical Care Pathway standardizes evaluation and management, ensuring a practical approach for clinicians. Future research should focus on optimizing real-world implementation and evaluating long-term patient outcomes. |
| Episodic Heavy Drinking and Implications for Steatotic Liver Disease Nomenclature: A National Cross-Sectional Study.
Episodic heavy drinking is prevalent in MASLD and associated with 3-fold higher odds of advanced liver fibrosis. Reclassifying these patients to MetALD would more than double the estimated prevalence of MetALD. |
| Higher doses of Bismuth and antibiotics do not improve H. pylori treatment effectiveness: results from the Hp-EuReg.
Increasing antibiotic or bismuth doses above the standard did not improve effectiveness of H. pylori treatment. Adherence, treatment length, and proton pump inhibitor co-therapy may be more impactful than escalation of antibiotics/bismuth doses. |
| Long-term Outcomes of Peroral Endoscopic Myotomy (POEM) versus Pneumatic Dilation after prior Laparoscopic Heller Myotomy for Achalasia.
POEM is more effective than PD at 5-year follow-up in achalasia patients after failed LHM. |
| Endoscopy |
| Beyond the Scope: A Global Perspective on gender disparity among advanced endoscopists.
Family responsibilities and perception of gender bias remain significant barriers to a career in advanced endoscopy for women worldwide. |
| Endoscopic ultrasound-guided gallbladder drainage in acute cholecystitis with contained perforation: a prospective cohort study (with video).
EUS-GBD appears technically feasible in patients with contained perforation, despite the additional complexity. However, this represents a particularly high-risk population, and the procedure may be considered for carefully selected patients in expert centers. |
| Prevalence and characteristics of sessile serrated lesions with dysplasia in Dutch fecal immunochemical test-positive screenees.
This study shows a 1.1% (1.1-1.1) prevalence of SSLD in FIT-positive screenees, offering valuable reference data. The finding that most SSLDs (64%) are small underscores the need to carefully assess small serrated polyps for dysplasia to ensure appropriate resection. |
| Gastroenterology |
| A Prospective Study of Gluten Transfer Through Kissing in Celiac-Discordant Couples.
There was not an increased risk of significant gluten transfer when kissing. Drinking 4 oz of water before kissing further reduces the risk. These results should guide our clinical practice and should be shared with our patients to help reduce the burden of the diet. |
| Fecal Hemoglobin-Guided Precision Post-polypectomy Surveillance within the Current Framework: A Four-Million-Participant FIT-based Screening Study.
fF-Hb-guided precision surveillance intervals can complement current guideline-based strategies by optimizing colonoscopy resource utilization while preserving the benefits of FIT-based CRC screening programs. |
| Gut |
| <i>Bifidobacterium catenulatum</i> boosts anti-PD-1 efficacy in microsatellite stable colorectal cancer via activating CD8<sup>+</sup> T cells.
Design The abundance of bacteria in CRC patients was evaluated in our in-house cohorts and validated in published datasets. The effect of candidate bacterium with anti-PD-1 therapy was determined in two syngeneic mouse models of MC38 (microsatellite instability-high) and CT26 (microsatellite stable, MSS), transgenic is a potential adjuvant to improve immunotherapy against CRC. |
| Quantifying artificial sweeteners and emulsifiers in Crohn's disease and its relationship with disease activity: the ENIGMA study - a novel and targeted approach.
This is the first human study to demonstrate distinct P-80 metabolism in patients with CD compared with controls. Dietary sweeteners and P-80 metabolites showed significant correlations with disease activity, suggesting their potential utility as non-invasive biomarkers for CD activity assessment. |
| RNA binding protein CAPRIN1 suppresses STAT1 translation and interferon signalling to promote HBV replication.
CAPRIN1 is elevated in IFN non-responders and further upregulated during HBV infection/replication. By facilitating stress granule formation and stabilising STAT1 rG4 structure, CAPRIN1 blocks ribosomal scanning and suppresses STAT1 translation. We therefore designate CAPRIN1 as a critical rheostat that calibrates the amplitude of IFN responses during innate immunity and adjuvant IFN-α therapy. |
| Selenoprotein P deficiency drives hepatocellular carcinoma progression via induction of neutrophil senescence and immunosuppressive microenvironment.
Sepp1 is a key regulator of neutrophil senescence-associated reprogramming and immune suppression in HCC through selenium-dependent epigenetic remodelling. Targeting senescent-like neutrophils via selenium supplementation holds therapeutic promise to enhance immunotherapy efficacy in liver cancer. |
| Hepatology |
| A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in chinese patients with chronic hepatitis B.
Pradefovir should be a highly recommended treatment option for adult patients with CHB. |
| A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis.
In this Phase 2a study, oral YAQ007 demonstrated short-term ammonia-lowering activity at doses ≥4 g BID. Given the exploratory design, these findings are hypothesis-generating and support further clinical evaluation. |
| HSP72 interacts with PRDX6 to deubiquitinate mitochondrial PINK1, activating mitophagy to treat MASLD.
These data suggest that the HSP72/PRDX6 axis is indispensable for PINK1/Parkin-dependent mitophagy to counteract MASLD. |
| Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with BCLC a hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial).
Neoadjuvant and adjuvant nivolumab in BCLC A HCC patients eligible for IRE lead to pathological response related to immune activation and show anti-tumoral effect. Clinicaltrialsgov identifier NCT03630640. |
| OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trial.
OCE-205 was well tolerated, with no evidence of excessive vasoconstriction or related events of ischemia or respiratory failure at any dose level. OCE-205 had a predictable, capped maximal efficacy that improved HRS-AKI in numerically more patients than placebo, though was underpowered for statistical significance. OCE-205 warrants additional investigation as a novel HRS therapy with a favorable benefit/risk profile. |
| Two decades of hepatitis E in solid organ transplantation: A retrospective monocentric analysis.
HEV infection is frequent in SOT recipients, with significant risks of chronicity and extrahepatic complications. Ribavirin remains the cornerstone of treatment, and individualized duration improves outcomes. Screening for HEV is mandatory in SOT patients with elevated liver enzymes. |
| J Hepatol |
| Chromatin remodeling in pericentral hepatocytes modulates MASH through CYP450 activity.
DPF2 in Lgr5 + hepatocytes is a critical regulator of hepatic metabolism, acting via the CYP2-atRA-AMPK axis. These findings reveal the mechanistic basis for zone-specific metabolic control in the liver and identify atRA homeostasis as a potential therapeutic target for MASLD and MASH. Impact and implications This study dissects chromatin regulation across defined hepatocyte populations in distinct liver zonations and demonstrates that DPF2 activity within a rare Lgr5 + hepatocyte subset is sufficient to drive metabolic reprogramming and MASLD progression. These findings are particularly important for liver researchers and clinicians, as they explain why liver-wide genetic manipulations or bulk omics analyses can obscure key disease-driving mechanisms confined to spatially restricted cell populations. From a translational perspective, our data suggest that targeting chromatin regulators or retinoid metabolic pathways may provide effective and safe therapeutic benefit; notably, systemic atRA administration can still confer robust protection or prevention at the whole-liver level. Although these implications are supported by rigorous mouse genetics, high-resolution transcriptomic analyses, and validation in human liver tissues, clinical translation will require confirmation in larger human liver cohorts and carefully designed patient studies. |
| Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort.
At 10 years, 17% of patients achieved off-treatment HBsAg loss, whereas more than half has been retreated. Patients with HBsAg levels <100 IU/mL benefit the most from NA cessation with a HBsAg loss rate of 52%. Based on our data, finite NA therapy is not recommended if HBsAg ≥1,000 IU/mL or in cirrhotic patients. Impact and implications Based on our study, we can conclude that finite NA therapy can be considered in patients with HBsAg levels <100 IU/mL when aiming for HBsAg loss, since they have the highest likelihood of achieving this endpoint (52%) and lowest need for retreatment (28%) during long-term follow-up, but only when strict monitoring can be guaranteed. In contrast, finite therapy is not recommended in patients with HBsAg levels ≥1,000 IU/mL or those with a history cirrhosis, especially as cirrhosis is a known risk factor for hepatic decompensation and HCC. In addition, our data can be used to further improve patient monitoring after finite NA therapy, especially in those who successfully remain off-therapy for five to ten years. Clinical trial number not applicable. |
| J Neurogastroenterol Motil |
| Belching and Reflux: The Relationship and the Underlying Mechanism.
This study demonstrated that belching might trigger reflux by increasing intragastric pressure, elevating the gastric-sphincter pressure gradient, which enables gastric contents to pass through the esophagogastric junction. These findings have crucial clinical significance, suggesting that reducing the occurrence of belching might be a potential treatment for refractory reflux. |
| Clinical Outcomes of Endoscopic Radiofrequency Stretta Therapy for Gastroesophageal Reflux Disease Treatment: A Retrospective Analysis From 2 Tertiary Centers in Korea.
Endoscopic radiofrequency Stretta therapy appears to be a safe treatment option for GERD and may provide favorable patient satisfaction and medication reduction. |
| DA-9701 for Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome: A Randomized Pilot Study.
DA-9701 did not improve GI symptoms in this crossover trial; however, its potential effect on specific GI symptoms merits further investigation. |
| Dysphagia is Associated With the Combination of Defective Bolus Transit and Poorly Relaxing Lower Esophageal Sphincter in Patients With Ineffective Esophageal Motility.
Dysphagia is a variable symptom associated with complex esophageal motility abnormalities. IEM patients with a combination of poorly relaxing LES and DBT are more likely to have dysphagia. |
| Patients' Knowledge, Attitudes, and Practices Regarding Non-pharmacological Treatments for Irritable Bowel Syndrome.
IBS patients exhibit a significant gap between their positive attitudes and their actual practices concerning non-pharmacological treatments. Knowledge is a direct driver of practice, but positive attitudes alone are insufficient to translate into behavior. Healthcare providers must move beyond simply fostering positive attitudes and focus on targeted educational interventions that provide actionable knowledge and skills to improve patient outcomes. |
| Real‑world Application of the International Anorectal Physiology Working Group Standardized Protocol and London Classification: A Multi‑country Cross‑sectional Survey of Anorectal Manometry Practice in Asia.
Across Asian centers, ARM practice shows marked regional variation and incomplete implementation of the IAPWG standardized protocol and London classification, highlighting persistent gaps in standardization. Strengthening procedural guidance, regionally appropriate normative data, and interpretation criteria through coordinated education and international collaboration is needed to support more consistent and clinically meaningful use of ARM in routine practice. |
| Semaglutide Induces Changes in Gastric Electrical Activity in Patients With Overweight and Obesity: A Pilot Study.
Semaglutide appears to alter gastric electrical activity on BSGM and increase early satiation, offering potential biomarkers for detecting drug effects. Further studies are needed. |
| Therapeutic Impact on Quality of Life in Adult Patients With Chronic Intestinal Pseudo-obstruction: A Multicenter, Cohort Study.
Patients with CIPO have a lower physical, psychological and social QOL, which is equivalent to or lower than that of adult patients with inflammatory bowel disease or psychiatric disorders. Sterilization of the intestinal tract and PEG-J decompression effectively improve the QOL of patients. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention. |
| Editorial: Low-Level Viraemia in Chronic Hepatitis B-A Benign State or Missed Opportunity? |
| Editorial: Peroxisome Proliferator-Activated Receptor Agonists-Shifting the Goalpost From Biochemical Response to Symptom Directed Therapy in PBC. |
| Editorial: Pushing Forward With Pharmacotherapies for Patients With Alcohol-Associated Cirrhosis. |
| Editorial: Two for the Price of One-GLP-1 Receptor Agonists Could Be More Effective Than MAUD in Patients With AUD and Metabolic Dysfunction. |
| Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies.
Pharmacologic treatment for MASH, including semaglutide, should be offered to patients with at-risk MASH who are at the highest risk of MALO. |
| Review Article: Ileal Bile Acid Transport (IBAT) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease.
IBAT inhibitors represent the first upstream pharmacotherapy targeting enterohepatic bile acid recirculation and are effective at reducing pruritus in ALGS and PFIC. Their role in PBC and PSC is promising yet undefined. Long-term studies are needed to assess effects on fibrosis progression, hepatocellular carcinoma risk and transplant-free survival. |
| Review Article: TL1A Inhibitors in IBD - Mechanistic Rationale and Clinical Evidence.
TL1A-DR3 integrates mucosal immunity with stromal injury, positioning inhibitors as a novel class to overcome IBD therapeutic ceilings by targeting the inflammation-fibrosis continuum. |
| Clin Gastroenterol Hepatol |
| Artificial Intelligence Tools for GI Research: A Practical Guide.
AI tools can meaningfully accelerate the GI manuscript writing workflow when used with appropriate safeguards. We propose a risk-stratified framework and emphasize that human verification of al AI-generated content remains essential. Transparent disclosure of AI use, consistent with current journal policies, should accompany al submissions. |
| Gastroenterology |
| Gastrointestinal Bleeding and Cardiovascular Risk: From Association to Actionable Evidence. |
| Monogenic and Polygenic Risk in Common Liver Diseases: Implications for Clinical Care.
Yet challenges remain, including limited ancestral diversity in genomic datasets, pleiotropic effects of variants, cost-effectiveness, and the need for integration with other omics and electronic medical records. As evidence matures, combining genetic risk with clinical and environmental factors may enable more personalized approaches to prognostication and therapy in liver disease. |
| Gastrointest Endosc |
| A note from the Editor-in-Chief. |
| Avoiding "Roux-do" surgery: lumen-apposing metal stents for partial endoscopic reversal of gastric bypass. |
| Bypassing obstacles. |
| Diagnosis of pancreatic cancers: beyond image enhancement. |
| Endoscopic resection for cervical esophageal squamous cell carcinoma: small space, big impact. |
| Endoscopic ultrasound-directed transenteric endoscopic retrograde cholangiopancreatography in surgically altered anatomy: one more step taken, many more to go. |
| Innovation begins with what we already have. |
| Optimizing traction-assisted endoscopic submucosal dissection: Is this novel robotic arm the much needed "helping hand"? |
| Repeat examination in patients with previous incomplete colonoscopy has a high success rate and yield of colorectal neoplasia. |
| Resect and repeat: Is this as good as it gets? |
| Submucosal tunneling endoscopic resection for subepithelial tumors: dissecting the outcome. |
| The role of artificial intelligence in colonoscopy performance and quality among gastroenterology fellows. |
| The state, health, and future of Gastrointestinal Endoscopy. |
| Toward the smart endoscopy center: evaluating the role of robots in the endoscopy unit. |
| Withdrawal time in colonoscopy: one size does not fit all. |
| J Neurogastroenterol Motil |
| Bridging the Therapeutic Gap: Clinical Efficacy of Endoscopic Radiofrequency Stretta Therapy for Gastroesophageal Reflux Disease in Korea. |
| From Belief to Behavior: Closing the Knowledge-Practice Gap in Irritable Bowel Syndrome Self-management. |
| Hydrogen and Methane Breath Test: The Asian Neurogastroenterology and Motility Association Monograph.
The Asian Neurogastroenterology and Motility Association hence presents the first Asian monograph guiding application and interpretation of breath test. The monograph was formulated according to the framework of indications, preparatory process, performance, and interpretation of results, as well as future direction for research. |
| Towards a Standard Protocol for Fecal Microbiota Transplantation in Irritable Bowel Syndrome.
Administering the donor's fecal transplant into the small intestine results in durable effects of FMT and long-term colonization of beneficial bacteria. A standard protocol for FMT with large and durable effects should include (1) careful donor selection, (2) handling the donor's fecal transplant in a way that preserves its microbiota contents, and (3) administering the transplant into the small intestine. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Artificial Intelligence in Clinical Gastroenterology: Promise, Pace, and Proof. |
| Calendar of Courses, Symposiums and Conferences. |
| Gastric Heterotopia in the Ileum Diagnosed with Combined EUS and Confocal Laser Endomicroscopy. |
| Letter to the Editor. |
| Mesenteric Volvulus: A Unique Complication of EUS-Guided Gastrojejunostomy. |
| Peritoneal Metastasis Mimicking Liver Metastasis in Rectal Cancer. |
| Response to Shen et al. |
| Spontaneous Autoamputation and Expulsion of Giant Colonic Lipoma. |
| Clin Gastroenterol Hepatol |
| Declining Opioid and Rising Nonopioid Analgesic Prescriptions Among 364,000 Veterans with Cirrhosis, 2010-2021. |
| Decreased dupilumab dosing frequency maintains long-term response in patients with eosinophilic esophagitis. |
| Fecal Microbiota Transplantation Rapidly Reduces Systemic Inflammation and Resolves C. difficile Pseudomembranous Colitis. |
| Endoscopy |
| Double-balloon enteroscopy-guided sclerotherapy for a rare case of blue rubber bleb nevus syndrome. |
| Endoscopic management of impacted basket in the pancreatic duct. |
| Endoscopic ultrasound-guided pancreaticogastrostomy using lumen-apposing metal stent to manage a case of pseudocyst and pancreatic duct dilation after severe acute pancreatitis. |
| Modified Zenker's peroral endoscopic myotomy for giant Zenker's diverticulum using a tunnel-free approach, undersaline immersion and mucosal trimming. |
| Trans-lumen apposing metal stent rendezvous technique for bile duct stone after the gallbladder drainage. |
| Gastroenterology |
| A Giant Gastric Ulcer: Not What It Seems. |
| Building the Human Liver in a Dish: Organoids, Assembloids and the Road to Precision Hepatology. |
| Intestinal smooth muscle macrophages: linking the ENS and CNS in Parkinson's disease. |
| Metabolomic pattern of ultra-processed food intake and risk of colorectal cancer precursors. |
| Peripheral Eosinophilia in a Patient With Subacute Watery Diarrhea. |
| Primary immunodeficiencies masquerading as Inflammatory Bowel Diseases. |
| SPINK1 p.Asn34Ser haplotype reduces pancreatic trypsin inhibitor mRNA in chronic pancreatitis patients undergoing TPIAT. |
| Gastrointest Endosc |
| A Case of Colorectal Lateral Spreading Tumor Associated with Schistosoma japonicum Infection. |
| Confocal Laser Endomicroscopy in the Diagnosis of Pharyngeal Neoplasms: An Optical Biopsy Approach. |
| Endoscopic resection of a symptomatic gastric fundus diverticulum (with video). |
| Endoscopic ultrasound mapping of the gastroepiploic vein in sinistral portal hypertension. |
| Management of Type IV Stent Misdeployment during EUS-Guided Gastroenterostomy. |
| Hepatology |
| Interpreting surgical associations in primary sclerosing cholangitis: Caution in clinical messaging. |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Letter: Attempted Validation of Villin-1 as a Gut Barrier Marker in Decompensated Cirrhosis-Potential Confounding by Tubular Injury and Aetiology. |
| Letter: Double PBC-Related Autoantibody Positivity-How Essential Is It for Diagnosis? |
| Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. |
| Letter: Steroid Tapering in Ulcerative Colitis-The Importance of Disease Severity and Maintenance Therapy. Authors' Reply. |
| Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy. |
| Letter: Steroid Tapering-Is Shorter Duration Better? Authors' Reply. |
| Clin Gastroenterol Hepatol |
| EUS-PPG: Standardising the Unknown in an Era of Non-Invasive Diagnostics. |
| Gastroenterology |
| Early-stage pancreatic cancer detected by a biomarker signature. |
| Methodological Considerations for the Serum Biomarker Panel in Early Detection of Pancreatic Cancer. |
| PancreaSure for Early PDAC Detection: Concerns Regarding Specificity in Symptomatic Cohorts and Organ Specificity. |
| PancreaSure: Ready for Real-World PDAC Surveillance, or Still Limited to a Highly Selected Cohort? |
| Response to Letters Regarding "Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma". |
| Gastrointest Endosc |
| Beyond resection with no residual microscopic disease: the critical role of histologic risk stratification in endoscopic management of suspected deep submucosal invasive colorectal cancer. |
| Endoscopic therapy for small neuroendocrine tumors of the rectum. |
| Refining cost-effectiveness modeling of colorectal cancer screening in average-risk Asian populations: implications of risk-based stratification and free screening policies. |
| Shifting the timing and readjusting the purpose of surveillance colonoscopy after piecemeal endoscopic mucosal resection of large colonic polyps in the era of margin thermal ablation. |
| J Hepatol |
| Artificial intelligence uncovers latent signals of portal hypertension in routine CT imaging. |
| Beyond binary classification of non-proportional hazards: methodological considerations for interpreting pivotal HCC trials. |
| Clonal T Cell Responses in CASH: Implications for Liver Metastasis. |
| Dynamic Changes in Cardiometabolic Risk Factors and Liver Stiffness in MASLD: Methodological Considerations. |
| From Human Genetics to Therapy: Targeting Alcohol and Steatotic Liver Disease via the FGF21 Liver-Brain Axis. |
| HBV infection occurred despite apparently adequate prophylaxis in a lung transplant recipient. |
| IL-22 unlocks large-scale in vitro hepatocyte expansion via STAT3 activation. |
| Letter in Response to Landscape of ALF Neuroprotection Without Invasive Monitoring. |
| Not yet time to A-Tango in redefining acute-on-chronic liver failure. |
| J Neurogastroenterol Motil |
| Resolution of Refractory Gastroparesis Symptoms Following Benzodiazepine Treatment for Catatonic Depression. |
| Substrate-dependent Differences of Colonic Hydrogen Production in a Patient With Fructose Malabsorption. |